BRPI0519023A2 - composiÇço farmacÊutica contendo pelo menos um derivado de dolastatina 10 - Google Patents
composiÇço farmacÊutica contendo pelo menos um derivado de dolastatina 10Info
- Publication number
- BRPI0519023A2 BRPI0519023A2 BRPI0519023-1A BRPI0519023A BRPI0519023A2 BR PI0519023 A2 BRPI0519023 A2 BR PI0519023A2 BR PI0519023 A BRPI0519023 A BR PI0519023A BR PI0519023 A2 BRPI0519023 A2 BR PI0519023A2
- Authority
- BR
- Brazil
- Prior art keywords
- pharmaceutical composition
- composition containing
- dolastatin derivative
- dolastatin
- derivative
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/282—Platinum compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
COMPOSIÇçO FARMACÊUTICA CONTENDO PELO MENOS UM DERIVADO DE DOLASTATINA 10. A presente invenção se refere a uma composição farmacêutica, compreendendo no mínimo um composto de fórmula (I) em combinação com capecitabina, trastuzumab, pertuzumab, cispiatina ou irinotecan para administração simultânea, seqüencial ou separada no tratamento de câncer.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP04106522 | 2004-12-13 | ||
EP05100866 | 2005-02-08 | ||
PCT/EP2005/012992 WO2006063707A2 (en) | 2004-12-13 | 2005-12-05 | Novel pharmaceutical composition containing at least one dolastatin 10 derivative |
Publications (1)
Publication Number | Publication Date |
---|---|
BRPI0519023A2 true BRPI0519023A2 (pt) | 2008-12-23 |
Family
ID=36113901
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0519023-1A BRPI0519023A2 (pt) | 2004-12-13 | 2005-12-05 | composiÇço farmacÊutica contendo pelo menos um derivado de dolastatina 10 |
Country Status (15)
Country | Link |
---|---|
US (1) | US20060292158A1 (pt) |
EP (1) | EP1827603A2 (pt) |
JP (1) | JP2008523002A (pt) |
KR (1) | KR20070086123A (pt) |
AR (1) | AR052046A1 (pt) |
AU (1) | AU2005315912A1 (pt) |
BR (1) | BRPI0519023A2 (pt) |
CA (1) | CA2590431A1 (pt) |
GT (1) | GT200500364A (pt) |
MX (1) | MX2007006430A (pt) |
PA (1) | PA8655401A1 (pt) |
PE (1) | PE20060747A1 (pt) |
RU (1) | RU2007126358A (pt) |
TW (1) | TW200635609A (pt) |
WO (1) | WO2006063707A2 (pt) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012123957A1 (en) * | 2011-03-16 | 2012-09-20 | Council Of Scientific & Industrial Research | Oligopeptides and process for preparation thereof |
BR112015024926A2 (pt) | 2013-04-16 | 2017-10-10 | Genentech Inc | composições, artigo de fabricação, métodos para tratar um paciente com câncer, para avaliar uma composição, para avaliar a atividade biológica, para produzir uma composição e para avaliar a fragmentação de uma composição e variante de pertuzumabe |
KR102384740B1 (ko) | 2013-12-27 | 2022-04-07 | 자임워크스 인코포레이티드 | 약물 접합체를 위한 설폰아마이드-함유 연결 시스템 |
AU2022338463A1 (en) | 2021-09-03 | 2024-03-21 | Toray Industries, Inc. | Pharmaceutical composition for cancer treatment and/or prevention |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4287523B2 (ja) * | 1998-12-28 | 2009-07-01 | あすか製薬株式会社 | 抗腫瘍剤 |
EP2289549A3 (en) * | 1999-10-01 | 2011-06-15 | Immunogen, Inc. | Immunoconjugates for treating cancer |
US6737409B2 (en) * | 2001-07-19 | 2004-05-18 | Hoffmann-La Roche Inc. | Dolastatin 10 derivatives |
US7968569B2 (en) * | 2002-05-17 | 2011-06-28 | Celgene Corporation | Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione |
-
2005
- 2005-12-05 EP EP05813987A patent/EP1827603A2/en not_active Withdrawn
- 2005-12-05 CA CA002590431A patent/CA2590431A1/en not_active Abandoned
- 2005-12-05 KR KR1020077013301A patent/KR20070086123A/ko not_active Application Discontinuation
- 2005-12-05 MX MX2007006430A patent/MX2007006430A/es not_active Application Discontinuation
- 2005-12-05 JP JP2007544793A patent/JP2008523002A/ja active Pending
- 2005-12-05 WO PCT/EP2005/012992 patent/WO2006063707A2/en active Application Filing
- 2005-12-05 AU AU2005315912A patent/AU2005315912A1/en not_active Abandoned
- 2005-12-05 BR BRPI0519023-1A patent/BRPI0519023A2/pt not_active Application Discontinuation
- 2005-12-05 RU RU2007126358/15A patent/RU2007126358A/ru not_active Application Discontinuation
- 2005-12-08 US US11/297,716 patent/US20060292158A1/en not_active Abandoned
- 2005-12-09 PE PE2005001424A patent/PE20060747A1/es not_active Application Discontinuation
- 2005-12-09 TW TW094143767A patent/TW200635609A/zh unknown
- 2005-12-12 PA PA20058655401A patent/PA8655401A1/es unknown
- 2005-12-12 GT GT200500364A patent/GT200500364A/es unknown
- 2005-12-12 AR ARP050105194A patent/AR052046A1/es not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
CA2590431A1 (en) | 2006-06-22 |
TW200635609A (en) | 2006-10-16 |
US20060292158A1 (en) | 2006-12-28 |
RU2007126358A (ru) | 2009-01-20 |
AU2005315912A1 (en) | 2006-06-22 |
PA8655401A1 (es) | 2006-08-03 |
AR052046A1 (es) | 2007-02-28 |
WO2006063707A3 (en) | 2006-10-26 |
EP1827603A2 (en) | 2007-09-05 |
WO2006063707A2 (en) | 2006-06-22 |
GT200500364A (es) | 2006-08-02 |
PE20060747A1 (es) | 2006-09-01 |
JP2008523002A (ja) | 2008-07-03 |
KR20070086123A (ko) | 2007-08-27 |
MX2007006430A (es) | 2007-07-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HUP0303271A2 (hu) | Rapamycin felhasználása rák kezelésére alkalmas gyógyszerkészítmény elõállítására | |
BRPI0622054B8 (pt) | composto e composição farmacêutica | |
MX2007009649A (es) | Derivados de meleimida, composiciones farmaceuticas y metodos para el tratamiento del cancer. | |
WO2007133637A3 (en) | Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same | |
BRPI0517567A (pt) | composto ou um sal, solvato, ou derivado fisiologicamente funcional farmaceuticamente aceitável do mesmo, composição farmacêutica, usos de um composto ou um sal, solvato, ou derivado fisiologicamente funcional farmaceuticamente aceitável do mesmo e de uma composição farmacêutica, e, processo para preparar um composto | |
ATE455786T1 (de) | 6-11 bicyclische ketolidderivate | |
WO2007128480A3 (en) | Thioglycosides as pharmaceutically active agents | |
EA201000091A1 (ru) | ПРОИЗВОДНЫЕ МОРФОЛИНОПИРИМИДИНА, ИСПОЛЬЗУЕМЫЕ ПРИ ЗАБОЛЕВАНИЯХ, СВЯЗАННЫХ С mTOR КИНАЗОЙ И/ИЛИ PI3K | |
BRPI0406883A (pt) | Composto, composição farmacêutica, método de tratar um distúrbio, e, uso de um composto | |
MY162319A (en) | Pharmaceutical composition comprising an omega-carboxyaryl substituted diphenyl urea for the treatment of cancer | |
EA200700601A1 (ru) | Производные фениламинопиримидина как ингибиторы bcr-abl | |
MY138708A (en) | Biaryloxymethylarenecarboxylic acids | |
NO20076425L (no) | Fremgangsmater for behandling av drug-resistent cancer | |
BR0309343A (pt) | Composto, composição farmacêutica, uso de um composto, e, método de tratamento ou profilaxia de doenças ou condições humanas | |
BR0309342A (pt) | Composto, composição farmacêutica, uso de um composto, e, método de tratamento ou profilaxia de doenças ou condições humanas | |
TW200639159A (en) | Treatment of pain | |
TW200626158A (en) | Naphthaline derivatives | |
WO2007024843A3 (en) | Pyrimidinyl-pyrazole inhibitors of aurora kinases | |
EA201001196A1 (ru) | Соединения 4-пиридинона и их применение для лечения рака | |
BRPI0507657A (pt) | composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, método para tratar um distúrbio, e, uso de um composto ou um sal farmaceuticamente aceitável do mesmo | |
BRPI0816798A2 (pt) | composto, composição farmacêutica, métodos para inibir a ação do glicogênio sintase cinase-3, e para tratar, prevenir ou melhorar uma doença, uso de um composto, e, artigo de fabricação | |
BRPI0715698B8 (pt) | produto, composição farmacêutica que o contém e uso de composto | |
WO2006108679A3 (en) | Substances and pharmaceutical compositions for the inhibition of glyoxalases and their use to combat cancer | |
EP2215054B8 (en) | Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same | |
CO6210702A2 (es) | Derivado de pirazolopirimidina |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing | ||
B11Y | Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette] | ||
B15K | Others concerning applications: alteration of classification |
Ipc: A61K 45/06 (2006.01), A61P 35/00 (2006.01) |